ARG1 and diabetes mellitus: Concerning safety considerations, to lower the toxicity of arginase inhibitors, it is necessary to take into account the inhibition potency of inhibitors on ARG1 and ARG2 and which isoform of arginase dominantly contributes to the pathogenesis of DM and its complications in different individuals.